Bayer and Onyx file for EU and US approval for expanded use of Nexavar; completes Steigerwald buy


German drug major Bayer (BAYN: DE) and US partner Onyx Pharmaceuticals (Nasdaq: ONXX) have filed for…

BayerBiotechnologyEuropeMergers & AcquisitionsNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulationSteigerwald

News briefs from Sanofi, Bayer, GlaxoSmithKline and Novartis


French drug major Sanofi (Euronext: SAN) has entered into a binding agreement to acquire the animal health…

BayerDosch PharmaceuticalsExjadeFlonaseGlaxoSmithKlineLegalMergers & AcquisitionsMerialNovartisOncologyPharmaceuticalregorafenibRegulationRespiratory and PulmonarySanofi

GlaxoSmithKline pulls sNDA for Tykerb plus Herceptin; Watson/Actavis update


UK pharma giant GlaxoSmithKline (LSE: GSK) revealed yesterday that it has withdrawn a supplemental New…

ActavisGenericsGlaxoSmithKlineHerceptinMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRegulationRocheTykerbWatson Pharmaceuticals

News briefs: GlaxoSmithKline and Bayer


UK pharma giant GlaxoSmithKline (LSE: GSK) has said it would not proceed with its $2.59 billion hostile…

Antibiotics and Infectious diseasesBayerGlaxoSmithKlineMergers & AcquisitionsOncologyPharmaceuticalregorafenibRegulationResearch

Shire to acquire FerroKin BioSciences; drops Replagal BLA


Ireland-headquartered Shire (LSE: SHP) said yesterday that it has signed an agreement to acquire privately-held…

FerroKin BioSciencesMergers & AcquisitionsNorth AmericaOncologyPharmaceuticalRare diseasesRegulationReplagalShire

UK's NICE gives final 'no' to NHS use of Novartis cancer drug Glivec; Novartis now holds 77% of Alcon


In another negative decision on the use of cancer drugs on the National Health Service in England and…

AlconGleevecGlivecMergers & AcquisitionsNovartisOncologyPharmaceuticalRegulation

News from Japan: Merck Serono’ Erbitux gets extended use; GlaxoSmithKline seeks acquisitions and sees flu vaccine order reduced


Merck Serono, a division of German drug major Merck KGaA says that Erbitux (cetuximab) can now be used…

Asia-PacificBiotechnologyErbituxGlaxoSmithKlineMerck KGaAMergers & AcquisitionsOncologyPharmaceuticalRegulationVaccines

Ark Thera slumps as it withdraws Cerepro MAA and looks at “strategic options”


UK-based Ark Therapeutics’ stock tumbled 11.1% yesterday, after the company said it was withdrawing…

Mergers & AcquisitionsOncologyPharmaceuticalRegulation



Back to top